GBS, a neurological condition triggered by an overactive immune system often after viral or bacterial infections, has been detected in Pune. Early sym ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Country-rap star Colt Ford got candid with People about his dramatic 60-pound weight loss following a near-fatal heart attack ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to ...